[
  {
    "ts": null,
    "headline": "Akebia Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights",
    "summary": "Vafseo® (vadadustat) Q3 2025 net product revenues grew to $14.3 million; Q3 2025 total net product revenues were $56.8 million Operational pilot of Vafseo at DaVita expected to complete in the fourth quarter; Access for 275,000 total patients across customer base expected by year-end Vadadustat post-hoc data analysis presented at ASN Kidney Week demonstrates composite of all-cause mortality and hospitalization outcomes statistically more favorable for patients receiving vadadustat compared to ES",
    "url": "https://finnhub.io/api/news?id=c37fde46c69f31a808eed3f6572b8a886d2392c8895b6504ec248e8da8afb571",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762776000,
      "headline": "Akebia Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights",
      "id": 137395505,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DVA",
      "source": "Yahoo",
      "summary": "Vafseo® (vadadustat) Q3 2025 net product revenues grew to $14.3 million; Q3 2025 total net product revenues were $56.8 million Operational pilot of Vafseo at DaVita expected to complete in the fourth quarter; Access for 275,000 total patients across customer base expected by year-end Vadadustat post-hoc data analysis presented at ASN Kidney Week demonstrates composite of all-cause mortality and hospitalization outcomes statistically more favorable for patients receiving vadadustat compared to ES",
      "url": "https://finnhub.io/api/news?id=c37fde46c69f31a808eed3f6572b8a886d2392c8895b6504ec248e8da8afb571"
    }
  },
  {
    "ts": null,
    "headline": "DaVita Stock: Analyst Estimates & Ratings",
    "summary": "DaVita has considerably underperformed the broader market over the past year, and analysts are cautious about the stock’s prospects.",
    "url": "https://finnhub.io/api/news?id=6139f4f53c1d96ccd4db8e53d4ff5fb667bc5506d07e175d7d21eacaef103ef8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762774863,
      "headline": "DaVita Stock: Analyst Estimates & Ratings",
      "id": 137395506,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DVA",
      "source": "Yahoo",
      "summary": "DaVita has considerably underperformed the broader market over the past year, and analysts are cautious about the stock’s prospects.",
      "url": "https://finnhub.io/api/news?id=6139f4f53c1d96ccd4db8e53d4ff5fb667bc5506d07e175d7d21eacaef103ef8"
    }
  }
]